Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Wainberg ZA"'
Autor:
Subbiah, V, Kreitman, RJ, Wainberg, ZA, Cho, JY, Schellens, JHM, Soria, JC, Wen, PY, Zielinski, CC, Cabanillas, ME, Boran, A, Ilankumaran, P, Burgess, P, Romero Salas, T, Keam, B
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 33, iss 4
BackgroundCombined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort
Autor:
Fuchs, Cs, Doi, T, Jang, Rw, Muro, K, Satoh, T, Machado, M, Sun, W, Jalal, Si, Shah, Ma, Metges, Jp, Garrido, M, Golan, T, Mandala', M, Wainberg, Za, Catenacci, Dv, Ohtsu, A, Shitara, K, Geva, R, Bleeker, J, Ko, Ah, Ku, G, Philip, P, Enzinger, Pc, Bang, Yj, Levitan, D, Wang, J, Rosales, M, Dalal, Rp, Yoon, Hh.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3982::fb1584cde5d65373c9d11689e437d464
http://hdl.handle.net/11391/1480816
http://hdl.handle.net/11391/1480816
Autor:
Cohen MJ, Wainberg ZA
Publikováno v:
Gastrointestinal Cancer : Targets and Therapy, Vol 2015, Iss default, Pp 73-77 (2015)
Melissa J Cohen,1 Zev A Wainberg2,3 1Division of Hematology and Oncology, University of California Los Angeles (UCLA), Porter Ranch, 2School of Medicine, 3Gastrointestinal Oncology Program, University of California Los Angeles (UCLA), Los Angeles, CA
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Autor:
Wainberg ZA; Division of Hematology/Oncology, Early Phase Clinical Research Program, Jonsson Comprehensive Cancer at UCLA, David Geffen School of Medicine, UCLA, Los Angeles, California.
Publikováno v:
Cancer discovery [Cancer Discov] 2024 Aug 02; Vol. 14 (8), pp. 1369-1371.
Autor:
Till JE; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., McDaniel L; Personalis, Inc., Menlo Park, CA, USA., Chang C; Indiana University School of Medicine, Indianapolis, IN, USA., Long Q; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Pfeiffer SM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Lyman JP; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Padrón LJ; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Maurer DM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Yu JX; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Gherardini PF; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Da Silva DM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., LaVallee TM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Abbott C; Personalis, Inc., Menlo Park, CA, USA., Chen RO; Personalis, Inc., Menlo Park, CA, USA., Boyle SM; Personalis, Inc., Menlo Park, CA, USA., Bhagwat N; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Cannas S; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Sagreiya H; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Li W; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Yee SS; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Abdalla A; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Wang Z; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Yin M; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Ballinger D; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Wissel P; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Eads J; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Karasic T; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Schneider C; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., O'Dwyer P; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Teitelbaum U; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Reiss KA; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Rahma OE; Dana-Farber Cancer Institute, Boston, MA, USA., Fisher GA; Stanford University, Stanford, CA, USA., Ko AH; University of California, San Francisco, San Francisco, CA, USA., Wainberg ZA; University of California, Los Angeles, Los Angeles, CA, USA., Wolff RA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA., O'Hara MH; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Vonderheide RH; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA., Carpenter EL; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA. erical@upenn.edu.
Publikováno v:
Nature communications [Nat Commun] 2024 Jul 09; Vol. 15 (1), pp. 5763. Date of Electronic Publication: 2024 Jul 09.
Autor:
Katoh M; M & M Precision Medicine, Tokyo, Japan., Nakayama I; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Wainberg ZA; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA., Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Katoh M; M & M Precision Medicine, Tokyo, Japan.; Department of Omics Network, National Cancer Center, Tokyo, Japan.
Publikováno v:
Clinical and translational medicine [Clin Transl Med] 2024 Jun; Vol. 14 (6), pp. e1736.
Autor:
Wainberg ZA; Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles Medical Center, David Geffen School of Medicine, 2825 Santa Monica Blvd., Suite 200, Santa Monica, Los Angeles, CA, 90404-2429, USA. ZWainberg@mednet.ucla.edu., Kang YK; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea., Lee KW; Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea., Qin S; Nanjing Tianyinshan Hospital, The 1st Affiliated Hospital of China Pharmaceutical University, Nanjing, China., Yamaguchi K; Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Kim IH; Department of Oncology, The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea., Saeed A; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA., Oh SC; Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea., Li J; Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China., Turk HM; Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey., Teixeira A; Gastroenterology Division, Hospital da Senhora da Oliveira, Guimarães, Portugal., Hitre E; Department of Medical Oncology and Clinical Pharmacology 'B', National Institute of Oncology, Budapest, Hungary., Udrea AA; Medical Oncology, Medisprof Cancer Center, Cluj-Napoca, Romania., Cardellino GG; Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy., Sanchez RG; Department of Medical Oncology, Catalan Institute of Oncology, Girona, Spain., Zahlten-Kümeli A; Amgen Inc, Thousand Oaks, CA, USA., Taylor K; Amgen Inc, Uxbridge, UK., Enzinger PC; Department of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2024 May; Vol. 27 (3), pp. 558-570. Date of Electronic Publication: 2024 Feb 03.
Autor:
Katoh M; M & M Precision Medicine, Tokyo, Japan., Loriot Y; Drug Development Department (DITEP), Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.; INSERM U981, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France., Brandi G; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Tavolari S; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Wainberg ZA; Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Katoh M; M & M Precision Medicine, Tokyo, Japan. mkatoh-kkr@umin.ac.jp.; Department of Omics Network, National Cancer Center, Tokyo, Japan. mkatoh-kkr@umin.ac.jp.
Publikováno v:
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2024 Apr; Vol. 21 (4), pp. 312-329. Date of Electronic Publication: 2024 Feb 29.
Autor:
Gardner FP; Florida Cancer Specialists and Research Institute, Cape Coral, FL 34471, USA., Wainberg ZA; UCLA School of Medicine, Los Angeles, CA 90095, USA., Fountzilas C; Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA., Bahary N; Allegheny Health Network Cancer Institute, Pittsburgh, PA 15212, USA., Womack MS; Tennessee Oncology, Chattanooga, TN 37129, USA., Macarulla T; Hospital Vall d'Hebrón, Vall d'Hebrón Institute of Oncology (VHIO), 08035 Barcelona, Spain., Garrido-Laguna I; Department of Internal Medicine, Huntsman Cancer Institute at University of Utah, Salt Lake City, UT 84112, USA., Peterson PM; Eli Lilly & Company, Indianapolis, IN 46285, USA., Borazanci E; HonorHealth Research Institute, Scottsdale, AZ 85258, USA., Johnson M; Tennessee Oncology, Nashville, TN 37203, USA., Ceccarelli M; Eli Lilly & Company, Sesto Fiorentino, 50019 Florence, Italy., Pelzer U; Medical Department, Division of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Publikováno v:
Cancers [Cancers (Basel)] 2024 Mar 28; Vol. 16 (7). Date of Electronic Publication: 2024 Mar 28.